Targeting HER proteins in cancer therapy and the role of the non-target HER3
Open Access
- 31 July 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 97 (4), 453-457
- https://doi.org/10.1038/sj.bjc.6603910
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Targeting the function of the HER2 oncogene in human cancer therapeuticsOncogene, 2007
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Nature, 2007
- Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJCI Insight, 2006
- Trastuzumab and breast cancer: developments and current statusInternational Journal of Clinical Oncology, 2006
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 2006
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer CellsMolecular and Cellular Biology, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987